These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 4778727)

  • 41. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 42. [Letter: International cooperation in drugs must be a simplification, not a complication].
    Thrane O
    Nord Med; 1974 Feb; 89(2):35-6. PubMed ID: 4820743
    [No Abstract]   [Full Text] [Related]  

  • 43. International drug regulation.
    Lee PR; Herzstein J
    Annu Rev Public Health; 1986; 7():217-35. PubMed ID: 3521644
    [No Abstract]   [Full Text] [Related]  

  • 44. [Nordic cooperation on drug control, registration, information. A Gordian knot?].
    Naess K
    Nord Med; 1974 Jan; 89(1):1-2. PubMed ID: 4819426
    [No Abstract]   [Full Text] [Related]  

  • 45. [Responsibility for adverse drug effects].
    Naess K
    Tidsskr Nor Laegeforen; 1971 Mar; 91(9):673-6. PubMed ID: 5576192
    [No Abstract]   [Full Text] [Related]  

  • 46. Inspections: the international regulatory view--Japan.
    Kamura S
    PDA J Pharm Sci Technol; 1994; 48(4):182-3. PubMed ID: 7804816
    [No Abstract]   [Full Text] [Related]  

  • 47. Spurious and counterfeit drugs: a growing industry in the developing world.
    Gautam CS; Utreja A; Singal GL
    Postgrad Med J; 2009 May; 85(1003):251-6. PubMed ID: 19520877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relative efficacy. When the government decides what drugs should be prescribed, is the patient better served?
    Ohio State Med J; 1972 Aug; 68(8):748-52 passim. PubMed ID: 5077306
    [No Abstract]   [Full Text] [Related]  

  • 49. Report on the Fifth European Symposium on Clinical Pharmacological Evaluation in Drug Control.
    Eur J Clin Pharmacol; 1977; 11(5):395-403. PubMed ID: 328291
    [No Abstract]   [Full Text] [Related]  

  • 50. The evolution of human medicines control from a national to an international perspective.
    Griffin JP
    Adverse Drug React Toxicol Rev; 1998 Mar; 17(1):19-50. PubMed ID: 9638280
    [No Abstract]   [Full Text] [Related]  

  • 51. [Questions on the monitoring of drug consumption at the 7th International pharmaceutical Congress held in Paris, July 16-21, 1978].
    Stika L
    Cesk Zdrav; 1979 Jul; 27(7):320-4. PubMed ID: 36993
    [No Abstract]   [Full Text] [Related]  

  • 52. [International efforts in the field of drug safety].
    Bertaux JF
    Soz Praventivmed; 1980 Mar; 25(1-2):23-5. PubMed ID: 7424174
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relative efficacy. When the government decides what drug should be prescribed, is the patient better served?
    J Med Assoc State Ala; 1972 Sep; 42(3):200-12. PubMed ID: 5070864
    [No Abstract]   [Full Text] [Related]  

  • 55. The medical ethics of clinical therapeutic trials.
    de Wet BS
    S Afr Med J; 1973 Jan; 47(1):18-21. PubMed ID: 4686243
    [No Abstract]   [Full Text] [Related]  

  • 56. Letter: Drug-imprint coding.
    Robertson WO
    JAMA; 1974 Aug; 229(7):766. PubMed ID: 4407815
    [No Abstract]   [Full Text] [Related]  

  • 57. The doctor and the pharmaceutical industry.
    Girdwood RH
    Br J Clin Pract; 1973 Aug; 27(8):279-84. PubMed ID: 4148588
    [No Abstract]   [Full Text] [Related]  

  • 58. Legal aspects of regulations pertaining to sale and distribution of analytical standards for drugs of abuse. I.
    Evans JG
    J Chromatogr Sci; 1972 May; 10(5):342-6. PubMed ID: 5066301
    [No Abstract]   [Full Text] [Related]  

  • 59. Unforeseeable adverse drug reactions: who should pay?
    Loveland D
    Med Law; 1985; 4(4):327-36. PubMed ID: 4046760
    [No Abstract]   [Full Text] [Related]  

  • 60. Post-marketing surveillance of adverse reactions to new medicines.
    Wilson AB
    Br Med J; 1977 Oct; 2(6093):1001-3. PubMed ID: 922357
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.